RxSight financials
$4.90+2.73%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M |
| Gross margin | 76.6% | 70.7% | 60.4% | 43.5% | 20.0% |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M | -$47.8M |
| Net income | -$38.9M | -$27.5M | -$48.6M | -$66.8M | -$48.7M |
| Net margin | −29.0% | −19.6% | −54.6% | −136.2% | −215.5% |
| Diluted EPS | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 |
| EBITDA | -$44.9M | -$33.3M | -$46.0M | -$59.4M | -$43.8M |
| Operating cash flow | -$15.5M | -$16.9M | -$41.6M | -$58.9M | -$44.7M |
| Free cash flow | -$19.3M | -$22.4M | -$46.4M | -$61.2M | -$46.6M |
| Diluted shares | 40.9M | 38.9M | 34.5M | 27.7M | 13.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $19.9M | $16.7M | $9.7M | $11.8M | $24.4M |
| Short-term investments | $208.2M | $220.5M | $117.5M | $94.0M | $135.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $40.2M | $39.8M |
| Total assets | $311.8M | $318.6M | $182.6M | $150.2M | $192.7M |
| Total liabilities | $36.1M | $37.3M | $22.2M | $60.3M | $54.5M |
| Shareholders' equity | $275.7M | $281.2M | $160.4M | $89.9M | $138.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology